Lu TX, Dapas M, Lin E, et al. - In patients with inflammatory bowel disease (IBD), this study was attempted to assess if proton pump inhibitors (PPIs) affect the response to infliximab therapy. Researchers collected patient-level data of adult patients with moderate-to-severe IBD treated with infliximab from the Yale Open Data Access Framework. Week 30 remission rates, week 54 remission rates, and hospitalization rates were evaluated via multivariable analysis and propensity score-matched analysis in patients on infliximab therapy with and without PPI exposure. There were 889 and 147 patients on infliximab with and without PPI therapy, respectively, among the five randomized controlled studies. Results demonstrated that patients with IBD taking PPI were less likely to achieve remission while on infliximab therapy in this patient-level meta-analysis of randomized controlled studies. The week 30 remission rates were 30% and 49% in patients with and without PPI therapy, respectively. The outcomes of this research need a future evaluation into the effect of PPI on IBD outcomes and therapies.